Bianca Calo
Nurse Practitioner · Houston, TXNPI 1184858540
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,840 of the $36,475 with a category attached, or 65.4%. AbbVie accounts for 62.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $10,388 and has fallen 57.3% since, to $4,432 in 2025. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 138 payments — averaging $264.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$23K
- Gilead$13K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$48
- Madrigal Pharmaceuticals$20
- Ipsen Biopharmaceuticals, Inc$19
- Dynavax Technologies Corporation$19
What the payments were for
- Consulting fees$8002%
- Speaking & faculty fees$23,84065%
- Travel & lodging$8,43123%
- Food & beverage$3,4049%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 85 | $22,931 |
| Gilead | 49 | $13,438 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $48 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,475 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lactulose | 11 | $412 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 15 | $303 |
| Omeprazole | 35 | $280 |
| Famotidine | 11 | $186 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Houston
- Melanie MorrisHouston$254K
- Julie WeatherlyHouston$87K
- Katrina KingHouston$44K
- Allison TurnerHouston$37K
- Tiffany RichardsHouston$37K
- Arby CohenHouston$23K
- Virginia MarxHouston$19K
- Hermeyone BellHouston$17K
- Cecilia DavisAustin$262K
- Stephanie BrownHarlingen$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.